A Phase 2 interventional study of Colchicine 0.5 mg and Placebo in HIV Infection and Cardiovascular Diseases (CVD), sponsored by Instituto de Investigación Hospital Universitario La Paz. Recruiting at 4 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Instituto de Investigación Hospital Universitario La Paz · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in HIV Infections with a site in Spain — 11 open to participants now, 21 under way, 8 of them phase 3. HIV Infections · Spain.
Among the 262 studies in HIV Infections with a site in Spain, this one is the 117th largest by planned enrollment of the 230 interventional ones that give a count, is one of 3 that started in 2026, is one of 39 in phase 2, reaches primary completion later than 18 of the 20 other live ones, and was the 262nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →11 of the 262 studies in HIV Infections with a site in Spain are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in Spain, United States, Australia and 5 more countries
Ages 18+
ViiV Healthcare · Sites in Spain, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in Spain, Belgium, France and 7 more countries
Ages 18+ · Healthy volunteers
Parc de Salut Mar · Sites in Spain
Ages 18+
Parc de Salut Mar · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 56 · Phase 3 87 · Phase 4 76
First in 1994; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 100 across the 230 interventional studies, 409 across the 28 observational. Of the 222 that completed or were terminated, 84 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 262 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Hospital Universitario La Paz is the lead sponsor of 104 studies on the registry; 14 are open to participants now.
Instituto de Investigación Hospital Universitario La Paz has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00825929Radboud University Medical CenterPharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | 2026-12 |
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 262 studies in HIV Infections with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clinical trial. Neither participants nor researchers will know which treatment is assigned during the study. The primary endpoint is the change in coronary artery inflammation measured by coronary computed tomography angiography (CCTA) after 96 weeks.
Despite advances in antiretroviral therapy, people living with HIV (PWH) have an increased risk of cardiovascular disease compared with the general population. Persistent inflammation and immune activation are considered important contributors to accelerated atherosclerosis and coronary artery disease in this population. Coronary inflammation is associated with cardiovascular risk, but strategies targeting this mechanism in PWH remain limited.
Colchicine is an anti-inflammatory drug that has demonstrated cardiovascular benefits in patients with coronary artery disease by reducing inflammatory pathways involved in atherosclerosis. However, the effect of colchicine on coronary artery inflammation in PWH has not been previously evaluated. The hypothesis of this study is that colchicine may reduce coronary artery inflammation in PWH with high cardiovascular risk.
This phase II, randomized, double-blind, multicenter, placebo-controlled trial will include approximately 90 participants who will receive colchicine or placebo for 96 weeks. Changes in coronary artery inflammation will be assessed using coronary computed tomography angiography (CCTA) and the perivascular fat attenuation index (FAI), a non-invasive imaging biomarker of vascular inflammation. The study will also evaluate safety and changes in cardiovascular and inflammatory markers during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Colchicine 0.5 mg orally once daily for 96 weeks.
Drug: Colchicine 0.5 mg
Matching placebo orally once daily for 96 weeks.
Drug: Placebo
Colchicine 0.5 mg administered orally once daily for 96 weeks as an anti-inflammatory treatment to reduce coronary artery inflammation in people living with HIV and high cardiovascular risk.
Matching placebo administered orally once daily for 96 weeks.
Changes in coronary artery inflammation
Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the three main coronary arteries (right coronary artery \[RCA\], left anterior descending artery \[LAD\], and left circumflex artery \[LCX\]). The mean FAI score will be calculated as the average of analyzable FAI scores with valid baseline and post-baseline measurements across the three coronary arteries.
Time frame: Baseline to Week 96
Changes in coronary plaque volume
Change from baseline in total coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Changes in coronary plaque burden
Change from baseline in coronary plaque burden assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in non-calcified plaque volume
Change from baseline in non-calcified coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in mixed plaque volume
Change from baseline in mixed coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in calcified plaque volume
Change from baseline in calcified coronary plaque volume assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in prevalence of positive remodeling plaques
Change from baseline in the percentage of coronary plaques presenting positive remodeling assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in prevalence of spotty calcium plaques
Change from baseline in the percentage of coronary plaques presenting spotty calcium assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in prevalence of napkin-ring sign plaques
Change from baseline in the percentage of coronary plaques presenting a napkin-ring sign assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in prevalence of low attenuation plaques
Change from baseline in the percentage of coronary plaques presenting low attenuation characteristics assessed by coronary computed tomography angiography (CCTA) at Week 96.
Time frame: Baseline to Week 96
Change in serum hsCRP concentration
Change from baseline in serum high-sensitivity C-reactive protein (hsCRP) concentration at Week 96.
Time frame: Baseline to Week 96
Change in serum IL-6 concentration
Change from baseline in serum interleukin-6 (IL-6) concentration at Week 96.
Time frame: Baseline to Week 96
Change in serum IL-1β concentration
Change from baseline in serum interleukin-1 beta (IL-1β) concentration at Week 96.
Time frame: Baseline to Week 96
Change in serum IL-18 concentration
Change from baseline in serum interleukin-18 (IL-18) concentration at Week 96.
Time frame: Baseline to Week 96
Change in serum SuPAR concentration
Change from baseline in soluble urokinase plasminogen activator receptor (SuPAR) concentration at Week 96.
Time frame: Baseline to Week 96
Change in extracellular vesicle NLRP3 levels
Change from baseline in NLRP3 levels in extracellular vesicles at Week 96.
Time frame: Baseline to Week 96
Change in extracellular vesicle ASC levels
Change from baseline in ASC levels in extracellular vesicles at Week 96.
Time frame: Baseline to Week 96
Change in extracellular vesicle Caspase-1 levels
Change from baseline in Caspase-1 levels in extracellular vesicles at Week 96.
Time frame: Baseline to Week 96
Change in classical monocyte proportion
Change from baseline in the proportion of classical monocytes (CD14++CD16-) at Week 96.
Time frame: Baseline to Week 96
Change in intermediate monocyte proportion
Change from baseline in the proportion of intermediate monocytes (CD14+CD16+) at Week 96.
Time frame: Baseline to Week 96
Change in non-classical monocyte proportion
Change from baseline in the proportion of non-classical monocytes (CD14++CD16++) at Week 96.
Time frame: Baseline to Week 96
Changes in leukocyte count
Percentage change of leukocyte count in week 96
Time frame: Baseline to Week 96
Changes in arterial inflammation in individual coronary vessels measured by Fat Attenuation Index (FAI)
Change from baseline in FAI and FAI score, including mean absolute change and mean percent change, assessed in individual coronary vessels (right coronary artery \[RCA\], left anterior descending artery \[LAD\], and left circumflex artery \[LCX\]).
Time frame: Baseline to Week 96
Mean arterial inflammation across analyzable coronary vessels measured by Fat Attenuation Index (FAI)
Mean absolute change from baseline in mean FAI and FAI score calculated as the average of analyzable coronary vessels with valid baseline and post-baseline measurements.
Time frame: Baseline to Week 96
Adverse events and serious adverse events
Incidence of solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs) during the study.
Time frame: Over the whole period of patient study participation
Sex-related differences in inflammatory patterns and treatment response
Difference in the percentage change of Fat Attenuation Index (FAI) between males and females in both treatment groups assessed by coronary computed tomography angiography (CCTA) in week 96.
Time frame: Baseline to Week 96
CYP2D6 genotype-related differences in treatment response
Difference in FAI percentage change according to CYP2D6 metabolizer classification in participants receiving colchicine.
Time frame: Baseline to Week 96
Major adverse cardiovascular events (MACE)
Difference in major adverse cardiovascular events (MACE) between colchicine and placebo groups assessed clinically in week 96.
Time frame: Baseline to Week 96
Cardiovascular risk score
Change from baseline in the CaRi-Heart risk score, including mean absolute change and mean percentage change.
Time frame: Baseline to Week 96
Start is estimated for Jun 2026; primary completion for Dec 2028, 30 months later.
Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 30 months is below that.
Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Instituto de Investigación Hospital Universitario La Paz →